Share

Huma Q. Rana

M.D., MPH

Clinical Director, Division of Cancer Genetics and Prevention

Senior Physician, Dana-Farber Cancer Institute

Assistant Professor of Medicine, Harvard Medical School

Huma Q. Rana, MD, MPH is the Clinical Director of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. At Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical management and the clinical operations that provide care to individuals with rare genetic susceptibilities to cancer. 

In addition to her clinical work, Dr. Rana leads multiple clinical research projects focused on developing cancer prevention and screening for those with hereditary cancer risk, and novel approaches to improving access to cancer genetics services. 

Dr. Rana received her medical degree from the Rutgers Robert Wood Johnson Medical School, completed her residencies in Internal Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai, and received her MPH from the Harvard T.H. Chan School of Public Health.  She has been a member of the Dana-Farber faculty since 2012.  

Huma Q. Rana

M.D., MPH

Clinical Director, Division of Cancer Genetics and Prevention

Senior Physician, Dana-Farber Cancer Institute

Assistant Professor of Medicine, Harvard Medical School

Huma Q. Rana, MD, MPH is the Clinical Director of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. At Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical management and the clinical operations that provide care to individuals with rare genetic susceptibilities to cancer. 

In addition to her clinical work, Dr. Rana leads multiple clinical research projects focused on developing cancer prevention and screening for those with hereditary cancer risk, and novel approaches to improving access to cancer genetics services. 

Dr. Rana received her medical degree from the Rutgers Robert Wood Johnson Medical School, completed her residencies in Internal Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai, and received her MPH from the Harvard T.H. Chan School of Public Health.  She has been a member of the Dana-Farber faculty since 2012.  

Recent Publications

Disparities in Tissue-based Biomarker Testing Among U.S. Medicare Beneficiaries with Prostate Cancer

Published On 2025 May 16

Journal article

CONCLUSION: This study reveals high geographic variability in tissue-based biomarker testing for prostate cancer. Further, Black and Hispanic patients were less likely to receive testing. Our findings highlight regional practice variation in the use of advanced, not routinely recommended tests and underscore the need to minimize disparities in diagnostic access.